The Effects of Dupilumab on Allergic Contact Dermatitis

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT03935971
Phase
PHASE4
Status
Active Not Recruiting

Conditions

  • Allergic Contact Dermatitis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.

Key Dates

Start date
Dec 18, 2019
Status verified
Feb 2026
Primary completion
Dec 31, 2024
Completion
Jul 31, 2026

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Subjects with Allergic Contact Dermatitis
    Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks

Primary Outcome Measure

Change From Baseline in Investigator's Global Assessment (IGA) Score [ Time Frame: week 0, week 6, week 12 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's Hospital, Department of DermatologyBostonMassachusetts02115-

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital, Department of Dermatology· Boston, MA

Related Studies